

Original Research Article
***In-vivo* Anti-Tumor Evaluation of
Dihydroartemisinin-Derived Endodisulphide on
MNU-Induced Liver Cancer in Sprague-Dawley Rats**

ABSTRACT

Aims: The study evaluated the antitumor potentials of a disulphide-substituted derivative of dihydroartemisinin (sDHA) on chemically induced cancer of the liver in Sprague-Dawley rats in comparison with its parent compound, dihydroartemisinin (DHA) and a standard anticancer drug.

Study Design: Animals are divided into ten groups (n=10 per group), and cancer is induced in all followed by administration of experimental agents, vehicle or distilled water.

Place and Duration of Study: Study was done in Faculty of Pharmacy, University of Uyo, Nigeria in 2015-2016.

Methodology: *N*-methy-*N*-nitrosourea, MNU (50 mg/kg) was administered intravenously as single dose to induce cancer in animal groups, followed by oral treatment with sDHA (37.42, 74.83 or 112.25 mg/kg/day), DHA (57.45, 114.89 or 172.34 mg/kg/day), cyclophosphamide (0.71 mg/kg/day) or Tween 30 (0.3 ml/day) for 28 days. Control group received distilled water (0.3 ml/day), while a group received only MNU (positive control). Drug treatments commenced 10 days after MNU injection and animals were observed for 52 days after drug treatments and sacrificed. Serum levels of CA-27-29, 8-OHdG and SOD were measured using ELISA method; and using immunohistochemical tissue staining techniques, Bcl-2 and Ki67 protein expressions were analyzed in hepatic cells.

Results: MNU caused elevation ($P < .0001$) in CA-27-29 and 8-OHdG; and reduction ($P < .0001$) in SOD. Hepatic cells of MNU alone treated rats demonstrated strong immunoreactivity for Bcl-2 and Ki67 ($\geq 75\%$). Oral treatments of sDHA or DHA resulted in dose-dependent reductions of MNU-induced CA-27-29 and 8-OHdG elevations ($P < .001$) but had no effect on SOD. Additionally, MNU induced Bcl-2 and Ki67 positive immunoreactive expressions were reduced to 25-50% by sDHA and DHA; DHA showing greater effect. Cyclophosphamide reversed all the MNU induced toxic effects.

Conclusions: sDHA possesses antitumor activity against liver cancer; has lesser efficacy than DHA, but both drugs are less effective than cyclophosphamide.

Keywords: *Dihydroartemisinin, Bcl-2, CA-27-29, liver cancer, MNU.*

34 1. INTRODUCTION

35 Cancers are among the leading causes of morbidity and mortality globally [1]. Different treatment
36 approaches exist for the disease, but chemotherapy (the use cytotoxic drugs) remains the first line of
37 treatment for many cancers [2,3]. Although, standard anticancer drugs can produce good responses
38 and survival, many unfortunately, are expensive, require frequent administration and cause serious
39 adverse effects (especially in combination). Thus, the search for anticancer drugs that are affordable
40 with high safety profiles while maintaining their efficacies continues.

41
42 Artemisinin derivatives are clinically used as antimalarial agents and have relative low host toxicity
43 [4,5]. They have equally been shown to possess potent anticancer activity against a variety of human
44 cancer models [6-8]. The presence of endoperoxide group in their molecules, have been shown to be
45 responsible for this anti-cancer activity, but their short half-lives [5], may be a limitation in their
46 utilization in cancer chemotherapy. It is envisaged that superoxide dismutase (SOD) enzyme, which is
47 present in human blood, readily breaks down the pharmacophore (endoperoxide group) of
48 artemisinins via its anti-peroxide action and this is thought to contribute to artemisinins short half-lives
49 [9]. In view of the above, it is hypothesized that structural modification of the endoperoxide ring of
50 artemisinins via substitution of the peroxide oxygen atoms with suitable atoms may resist SOD effect
51 and extend their half-lives, which has led to the synthesis of a disulphide derivative of DHA, the active
52 metabolite of artemisinin [10]. The new drug was synthesized through structural modification of DHA
53 by replacing its peroxide oxygen atoms with disulphide, or persulphide [10]. With the synthesis of this
54 new compound, it would be reasonable to evaluate its pharmacokinetic, toxicity and anticancer
55 profiles. Acute toxicity evaluation of the disulphide derivative of DHA has been done in our earlier
56 study [11]. It has also been demonstrated to exhibit remarkable dose related anti-malaria effect in rats
57 which compared favorably with DHA [10], but it is not yet known whether it would maintain or possess
58 higher anticancer activity with respect to the parent drug.

59
60 This study was therefore intended to conduct an *in-vivo* evaluation of the antitumor potential of
61 disulphide substituted derivative of DHA on *N*-Methyl-*N*-Nitrosourea (MNU) induced liver cancer in
62 Sprague-Dawley rats in comparison with the parent drug.

63

64 2. MATERIALS AND METHODS

65 2.1 Materials

66 2.1.1 Equipment

67 Microplate reader (Biotek, USA), pH meter (Denver Instrument, Model: 215, New York, USA),
68 centrifuge (Zeny Inc., Model: 800-1, Salt Lake, USA), UV/Visible spectrophotometer (Biotek, Model:
69 7305, Winooski, USA), rotary microtome (Leica Biosystem, Model: Leica RM 2125, Germany), wax
70 dispenser (MH 85523B, United Kingdom), Microfield digital laboratory oven (Model: SM90234,
71 England), automatic tissue processor (Leica TP1020, Germany), digital Olympus microscope (Model:
72 XXT/300, Germany) and autoclave (Lifesterware Pvt Ltd., Delhi, India) were among the equipment
73 used for the study.

75 2.1.2 Drugs

76 Pure powder of dihydroartemisinin (DHA) and disulphide derivative of DHA (sDHA) were obtained
77 from the Department of Medicinal and Pharmaceutical Chemistry, Faculty of Pharmacy, University of
78 Uyo, Nigeria. Cyclophosphamide (Endoxan[®]) tablets (Zyus Biogen- Baxter, Mumbai, India), was
79 purchased from the Pharmacy Unit of the University of Uyo Teaching Hospital, Uyo, Nigeria.

81 2.1.3 Reagents

82 CA 27-29 assay kit (Cell Biolabs Inc., San Diego, CA 92126, USA), 8-OHdG assay kit (Cell Biolabs
83 Inc., San Diego, CA 92126, USA), SOD assay kit (Cell Biolabs Inc., San Diego, CA 92126, USA), Bcl-
84 2 assay kit (BioVision Inc. 155 South Milpitas Blvd., Milpitas, California 95035, USA), Ki67 assay kit
85 (BioVision Inc. California 95035, USA) and haematoxylin and Eosin stain kit (Sigma- Aldrich Inc. St.
86 Louis, MO 63178. USA) were among reagents used for the study.

88 2.1.4 Chemicals

89 *N*-Methyl-*N*-Nitroso urea, MNU (Sunglong Biotech Co. Ltd, Zhejiang, China), ketamine HCl (Merck,
90 Darmstadt, Germany), xylazine (Taj Pharmaceutical Limited, Mumbai, India), polysorbate (Tween[®])
91 80 (Sigma-Aldrich and Merck, KGaA, Darmstadt, Germany), paraffin wax (Megha Group of
92 Companies, Meghalaya, India), TRIS-acetate-EDTA buffer (Sigma-Aldrich Inc. St. Louis, MO

63178. USA), and phosphate buffer saline (Sigma- Aldrich Inc. St. Louis, MO 63178. USA), xylene (Taj Pharmaceutical Limited, Mumbai, India) were among chemicals used for the study.

2.1.5 Animals

Adult Sprague-Dawley rats, aged 6-8 weeks old, weighing 180-200 g were used for the study. They were housed in plastic cages and maintained under standard conditions (12 h light-dark cycle, and room temperature). The rats were given free access to clean water and commercial rodent chow and allowed to acclimate for two weeks before commencement of experiment. Experimental procedures were approved by the Ethics Committee on Research, University of Port Harcourt, Nigeria. Animals were handled according to standard guidelines for care and use of laboratory animals [12]

2.2 Methods

2.2.1 Experimental Design

One hundred rats (180-200 g) were randomly distributed into ten groups (labelled as groups 1-10) containing 10 animals per group. Groups 1 to 8 were administered *N*-Methyl-*N*-Nitrosourea (MNU) as a single dose (50 mg/kg) through the jugular vein to induce cancer [13]. Ten days after MNU administration, group 1-7 animals were treated orally with DHA (57.45, 114.89 or 172.34 mg/kg body weight), sDHA (37.42, 74.83 or 112.25 mg/kg body weight) or cyclophosphamide (0.71 mg/kg body weight) continuously for 28 days. The ninth group was given Tween 80 (0.3 ml) and the tenth (control) group received distilled water (0.3 ml). MNU was dissolved in physiological saline (1 % w/v) buffered to pH 5.0 with 3 % acetic acid, whereas the drugs, except cyclophosphamide were dissolved in Tween 80 (30 %). Cyclophosphamide was dissolved in distilled water. The doses of sDHA and DHA corresponded to 10, 20 and 30 % of their LD₅₀ [11], while the dose of cyclophosphamide was equivalent to its therapeutic dose for cancer chemotherapy [14].

After the drug administrations, the rats were observed without treatment for additional 52 days. On the 91st day of the experiment, the animals were anesthetized with ketamine/xylazine (150/10 mg/kg) and sacrificed by cervical dislocation. Blood was collected by cardiac puncture and blood serum was used to analyze specific biochemical cancer biomarkers: cancer antigen (CA-27-29), 8-hydroxydeoxyguanosine (8-OHdG) and superoxide dismutase (SOD). Livers were carefully removed

and fixed in neutral buffered formalin for less than 24 h and immunohistochemically analyzed afterwards.

2.2.2 Measurement of Cancer Biomarkers

The cancer biomarkers analyzed were- CA 27-29, 8-OHdG and SOD. Briefly, blood serum (10 µl) and the sample dilution buffer (40 µl) was mixed in an antibody pre-coated micro ELISA strip plate specific for CA 27-29, 8-OHdG or SOD and incubated at 37°C for 30 min. The wells of the plates were washed and horseradish peroxidase (HRP)-conjugated antibody (50 µl) specific for CA 27-29, 8-OHdG or SOD was added and incubated at room temperature. TMB substrate solution- chromogenic solution A and B (50 µl each) was then added and incubated at 37°C for 15 min after proper mixing with sample solution in wells. Finally, the reaction was terminated with 0.16 M sulfuric acid (stop solution) and CA 27-29, 8-OHdG or SOD concentration was measured spectrophotometrically at 450 nm.

2.2.3 Immunohistochemical Analysis (Bcl-2 and Ki67)

Immunohistochemistry was performed with the following primary and secondary antibodies: (1) Bcl-2 primary antibodies- mouse anti-Bcl-2 monoclonal antibody, C-2 (Santa Cruz Biotechnology, Santa Cruz, CA 95060). (2) Ki67 primary antibodies- mouse anti-rat Ki-67 antibody, MIB-5 (Dakocytomation corporation Carpinteria, CA 94010). (3) Bcl-2 and Ki67 secondary antibodies- biotinylated horse anti-mouse IgG, H+L (Vector Laboratories Inc., Burlingame, CA 94010). Tissue sections of liver (5-µm) were deparaffinised in 3 changes of xylene, hydrated through graded ethyl alcohol and rinsed in 3-4 changes of buffered phosphate, ending with a distilled water rinse. After removing excess water, 3 % hydrogen peroxide was applied to the tissues and incubated for 5 min. The slides used were previously preheated (95°C) in a target retrieval solution for 20 min, allowed to cool for 20 min at room temperature, rinsed gently, and placed in Tris buffer bath for 5 min. Primary antibodies for Bcl-2 or Ki67 were applied unto the tissue specimens and incubated for 10 min. Slides were washed in buffer and incubated with the secondary antibodies for 10 min. Sufficient freshly prepared 3,3'-diaminobenzidine (DAB) solution (the chromogen) was applied and incubated for 5 min for color detection. Tissues were lightly counterstained with Mayer's haematoxylin, blued in warm tap water, dehydrated through ascending grade of alcohol, cleared in xylene, cover-slipped and mounted with a compatible mounting medium. Positively stained cells for Bcl-2 or Ki-67 expression were identified by

brown nuclear or cytoplasmic staining against light blue background, respectively. Specimens were considered immunopositive when more than 10% of cells showed clear evidence of immunostaining.

2.2.4 Statistical Analysis

Analysis of data was carried out using GraphPad Prism Version 6 and all data were expressed as mean±standard error of mean (mean±SEM). Differences among treatment groups were analyzed using one way analysis of variance (ANOVA) followed by Newman-Keuls Multiple Comparison Test for intra group comparisons. Values were considered significant at $P < .05$.

3. RESULTS AND DISCUSSION

3.1 Results

3.1.2 Serum Levels of Cancer Biomarkers

The results showed that there were no significant differences ($P > .05$) between the serum levels of CA 27-29 (cancer antigen), 8-OHdG (DNA oxidative product) and superoxide dismutase (SOD) in Tween 80 (vehicle) treated group and distilled water treated (control) group (Figures 2-4). In addition, serum levels of CA 27-29 and 8-OHdG were significantly increased ($P < .001$) in MNU-treated group of rats, while SOD was decreased ($P < .001$) compared to control group (Figures 2-4).

In dihydroartemisinin (DHA) or disulphide-substituted derivative of DHA (sDHA) treated groups, the serum levels of CA 27-29 and 8-OHdG were decreased ($P < .001$) compared to MNU-treated group. When compared with control, the CA 27-29 value that was obtained in high dose (172.34 mg/kg) DHA treated group was not significantly different, but all other values were higher (Figures 2 and 3). CA 27-29 and 8-OHdG concentrations were equally reduced ($P < .001$) in cyclophosphamide treated rats compared to MNU alone treated rats, and the values were although, higher but not significantly different ($P = .05$) when compared with control (Figures 2 and 3). The serum levels of SOD in all DHA or sDHA administered rats were lower ($P < .001$) than control (Figure 4). The values obtained were also not significantly different from the MNU-induced level, except in the group that received high dose DHA, which had a higher ($P < .001$) level (Figure 4). SOD level was increased in cyclophosphamide ($P = .01$) treated rats compared with MNU treated rats, but the value was lower ($P < .001$) when compared with control (Figure 4).

Further, when DHA and sDHA effects were compared, sDHA inhibition of MNU-induced serum elevations in CA 27-29 and DNA 8-OHdG was lower, mostly at the low and mid doses, $P = 0.01$, $P < .001$ (Figures 2 and 3). Also, only DHA inhibited MNU's effect on SOD, which was observed only in the high dose treated group (Figure 4). However, the effects of DHA and sDHA were significantly lower ($P < .001$) when compared with cyclophosphamide (Figures 2-4).

3.1.2 Immunohistochemistry

Liver cells of rats treated with distilled water (control) showed negative expression of Bcl-2 and Ki67 (<5 % positivity), whereas MNU treatment caused strong positive immunoreactive expressions (>75 % positivity) of Bcl-2 and Ki67 (Figures 5 and 6). Liver cells of rats that received DHA or sDHA showed positive Bcl-2 expression; reactivity obtained was <75, <50 and <25 % positivity, respectively (Figure 5). Ki67 was expressed differently in DHA and sDHA treated rats: positive expression was observed in all sDHA treated rats (reactivity <60, <50 and <50 % positivity, respectively), whereas it was positive only in rats that received low and mid doses of DHA, <25, <25 and <10 % positivity, respectively (Figure 6). In addition, the liver cells of cyclophosphamide treated rats showed negative Bcl-2 and Ki67 expressions (<5 or 10 % positivity) as shown in Figures 5 and 6.

3.2 Discussion

This study reports the antitumor potential of a newly synthesized derivative of dihydroartemisinin (DHA) in comparison with the parent drug. The new compound being investigated is a sesquiterpene disulphide substituted derivative of DHA (sDHA) believed to have an extended half-life than the parent drug. Preliminary studies on the new drug have shown that the drug exhibits an antiplasmodia effect in rats which compared favorably with the parent drug [9], but its anticancer activity was yet to be investigated prior to this study.

In this study, three doses (low, medium and high) of sDHA and DHA, equivalent to 10, 20 and 30 % of their LD₅₀, respectively were used, while cyclophosphamide was used as a standard anticancer drug. Further, *N*-Methyl-*N*-Nitrosourea (MNU) was used to induce cancer in the liver of Sprague-Dawley rats in this study. This model has been used extensively to test the preventive potential of a variety of chemical compounds and interventions [12,15]. Specific biochemical and immunohistochemical

cancer biomarkers were evaluated which included- CA 27-29, 8-hydroxydeoxyguanosine (8-OHdG), superoxide dismutase (SOD) enzyme, B-cell lymphoma 2 (Bcl-2) and Ki67.

From our results, MNU induced marked elevations in serum levels of CA 27-29 and 8-OHdG and reduction in SOD enzyme, indicative of cancer development in target tissues [16-19]. The immunohistochemistry results showed that the liver cells of rats that received only distilled water demonstrated negative Bcl-2 and Ki67 expressions (<5 % positive); whereas there were very strong positive immunoreactive nuclear/cytoplasmic expressions of Bcl-2 and Ki67 (>75 % positive) in the hepatic cells of MNU-injected rats without drug treatment. Bcl-2 is a protein that regulates cell death (apoptosis) in the body, basically by either inducing (proapoptotic) or inhibiting (anti-apoptotic) apoptosis. Bcl-2 is specifically considered an important anti-apoptotic protein and is thus classified as an oncogene [20]. Ki-67 is a specific nuclear marker for cell proliferation, and overexpression is frequently seen in a variety of malignant tissues [21-23]. The strong positive expressions of Bcl-2 and Ki-67 in MNU treated rats therefore confirms the presence of cancer in livers of the treated rats.

sDHA or DHA treatment decreased the MNU-induced elevations of CA 27-29 and 8-OHdG dose-dependently. However, both drugs failed to normalize levels of these cancer biomarkers, except CA 27-29 that was reduced to comparable level as control by DHA at the high dose. On the other hand, the drug treatments generally produced no effect on the MNU-induced reduction of SOD, except the high dose of DHA which was not sufficient to normalize SOD level. These findings indicate that DHA and sDHA can ameliorate cancer development, but may have little effect on cancers predominantly mediated by superoxide anion oncogenic activity, as SOD enzyme was minimally affected by both drugs. Additionally, the effects of the two drugs were generally comparable, although, DHA exhibited higher effects at few doses. Further, cyclophosphamide, which was used as a reference drug in this study, produced greater levels of inhibition of the MNU-induced biochemical toxicities than sDHA or DHA, and equally reversed the MNU effects.

Furthermore, sDHA and DHA treatments reduced Bcl-2 and Ki67 expressions in liver in dose-dependent manners. High dose treatment of both drugs completely reversed MNU induced Ki67 expression but not Bcl-2 in liver. The results also showed that DHA produced greater inhibitory activity

of Bcl-2 and Ki67 expressions in the liver and may therefore be more effective than sDHA. Cyclophosphamide treatment ameliorated Bcl-2 and Ki67 expressions better than DHA or sDHA, as it reversed MNU induced expressions of the two cancer biomarkers. The results indicate that DHA and sDHA possess ability to reduce MNU-induced tumor activities in the liver, but lack recovery and may not compete favorably with cyclophosphamide in efficacy. However, the results are indicative of a possibility of obtaining greater effectiveness using higher dose levels of the drugs. This is a potential area of future study.

4. CONCLUSION

The study reveals that anticancer activity is not lost in disulphide-substituted dihydroartemisinin, a new drug obtained through structural modification of dihydroartemisinin. The new drug possesses potential antitumor activity against MNU-induced liver cancer. Over the dose range used, the drug has lesser efficacy than the parent drug (dihydroartemisinin), and neither the new drug nor dihydroartemisinin has comparable efficacy with cyclophosphamide. Future studies using higher doses of the new drug is recommended.

COMPETING OF INTERESTS

None

CONSENT

Not applicable.

ETHICAL APPROVAL

The experimental procedures were approved by the Research Ethics Committee of University of Port Harcourt, Nigeria.

REFERENCES

1. WHO- World Health Organization. Cancer; Fact Sheet No. 297. Geneva, Switzerland; 2015.
2. Leighl NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. *Curr Oncol*. 2012;19(Suppl 1):S52-8.
3. Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: Developments and potentials. *Int J Cancer* 2014;134:1257–69.
4. de Vries, PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. *Drugs* 1996;52(6):818-36.
5. Na-Bangchang KS, Krudsood U, Silachamroon P, Molunto O, Tasanor K, Chalermrut N, *et al*. The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. *Southeast Asian J Trop Med Public Health* 2004;35(3):575-82.
6. Jiao Y, Ge CM, Meng HG, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. *Acta Pharmacol Sin*. 2007;28(7):1045–56.
7. Lu YY, Chen TS, Qu JL, Pan WL, Sun L, Wei XB. Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. *J Biomed Sci*. 2009;16:16.
8. Crespo-Ortiz MP, Wei MQ. Anti-tumor activity of artemisinin and its derivatives: From a well-known anti-malarial agent to a potential cancer drug. *J Biomed Biotech*. 2012;15:1705-21.
9. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. *J Clin Invest*. 2003;111:583-93.
10. Bassey UB. Synthesis, characteristics and antimalarial study of the deoxy and disulphide derivatives of dihydroartemisinin. M.Sc Thesis, Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Uyo, Nigeria. Supervisor: Prof. E.E. Essien; 2015.
11. Udoh IM, Aprioku JS, Siminialayi IM. Acute and sub-acute toxicity evaluation of disulphide derivative of dihydroartemisinin. *World J Pharm Res*. 2016;6(1):77-95.
12. CCAC- Canadian Council On Animal Care. The Care and Use of Farm Animals in Research, Teaching and Testing. 12-15. Ottawa; 2009.
13. Parikh RR, Gildener-Leapman N, Narendran A, Lin H, Lemanski N, Bennett JA, *et al*. Prevention of N-Methyl-N-Nitrosourea-Induced Breast Cancer by α -Fetoprotein (AFP)-Derived Peptide, a Peptide Derived from the Active Site of AFP. *Clin Cancer Res*. 2005;11:8512-20.

- 304 14. BNF- British National Formulary. London, UK: BMJ Group and Royal Pharmaceutical Society;.
305 2013.
- 306 15. Verma S, Bahorun T, Singh RK, Aruoma OI, Kumar A. Effect of Aegle marmelos leaf extract
307 on N-methyl N-nitrosourea-induced hepatocarcinogenesis in Balb/c mice. Pharm Biol. 2013;51(10):
- 308 16. Clinton S, Beason K, Bryant S, Johnson J, Jackson M, Wilson C, *et al.* A comparative study of
309 four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum.
310 2003;39:408-14.
- 311 17. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): a critical bio-
312 marker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog
313 Ecotoxicol Rev. 2009;27:120–39.
- 314 18. Alscher RG, Erturk N, Heath LS. Role of superoxide dismutases (SODs) in controlling oxidative
315 stress in plants. J Exp Bot. 2002;53(372):1331–41.
- 316 19. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, *et al.* Mitogenic signaling mediated by
317 oxidants in Ras-transformed fibroblasts. Science 1997;275(5306):1649–52.
- 318 20. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-
319 2/immunoglobulin transcript resulting from the (14;18) translocation. Cell 1986;47(1):19-28.
- 320 21. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol.
321 2000;182(3):311–22.
- 322 22. Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human
323 astrocytomas. Pathol Oncol Res. 2006;12:143–7.
- 324 23. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early
325 breast cancer: a systematic review and met-analysis of 85 studies in 32,825 patients. Breast
326 2008;17:323-34.
- 327




Fig. 1. Chemical structures of artesunate and dihydroartemisinin and their disulphide derivatives




Fig 2. Effects of 28 days administration of dihydroartemisinin (DHA), disulphide-substituted DHA (sDHA) and cyclophosphamide (cyclophos) on MNU-induced elevation of serum CA-27-29 antigen level in Sprague-Dawley rats

Test drugs, significant from control, * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$

Test drugs, significant from MNU, ^a $P = 0.01$; ^β $P < 0.001$

sDHA treatment, significant from DHA, [†] $P = 0.01$

Test drugs, significant from cyclophosphamide, ^φ $P < 0.05$; [#] $P < 0.001$

Mean $\pm$ S.E.M = Mean values $\pm$ Standard error of means of ten experiments




Fig 3. Effects of 28 days administration of dihydroartemisinin (DHA), disulphide-substituted DHA (sDHA) and cyclophosphamide (cyclophos) on MNU-induced elevation of serum 8-hydroxydeoxyguanosine, 8-OHdG (cell DNA damage marker) level in Sprague-Dawley rats

*Test drugs, significant from control, * $P < 0.001$*

Test drugs, significant from MNU, β $P < 0.001$

sDHA treatment, significant from DHA, $\dagger$ $P = 0.001$

Test drugs, significant from cyclophosphamide, $\#$ $P < 0.001$

Mean $\pm$ S.E.M = Mean values $\pm$ Standard error of means of ten experiments




Fig. 4. Effects of 28 days administration of dihydroartemisinin (DHA), disulphide-substituted DHA (sDHA) and cyclophosphamide (cyclophos) on MNU-induced reduction of serum superoxide dismutase (SOD) enzyme level in Sprague-Dawley rats

*Test drugs, significant from control, * $P < 0.001$*

Test drugs, significant from MNU, ^α $P < 0.01$; ^β $P < 0.001$

sDHA treatment, significant from DHA, [†] $P < 0.01$

Test drugs, significant from cyclophosphamide, ^φ $P < 0.05$; [#] $P < 0.01$

Mean $\pm$ S.E.M = Mean values $\pm$ Standard error of means of ten experiments











Fig 5. Photomicrographs showing hepatic cell expression of Bcl-2 antigen in MNU treated and MNU plus DHA, sDHA or cyclophosphamide treated Sprague-Dawley rats (Bcl-2 immunohistochemical method, x400)

A: Liver of animals treated with distilled water (Control), showing negative immunoreactive nuclear expression for Bcl-2 (less than 5 % positivity).

B: Liver of animals treated with MNU (50 mg/kg) alone, showing strong positive immunoreactive nuclear expression for Bcl-2 (more than 75 % positivity).

C: Liver of animals treated with MNU plus cyclophosphamide (0.7 mg/kg), showing negative immunoreactive nuclear expression for Bcl-2 (less than 5 % positivity).

D: Liver of animals treated with MNU plus DHA (54.8 mg/kg), showing strong positive immunoreactive nuclear expression for Bcl-2 (less than 75 % positivity).

E: Liver of animals treated with MNU plus DHA (109.5 mg/kg), showing strong positive immunoreactive nuclear expression for Bcl-2 (less than 50 % positivity).

F: Liver of animals treated with MNU plus DHA (164.3 mg/kg), showing positive immunoreactive nuclear expression for Bcl-2 positive (less than 25 % positivity).

G: Liver of animals treated with MNU plus sDHA (34.6 mg/kg), showing strong positive immunoreactive nuclear expression for Bcl-2 (less than 75 % positivity).

H: Liver of animals treated with MNU plus sDHA (69.3 mg/kg), showing strong positive immunoreactive nuclear expression for Bcl-2 (less than 50 % positivity).

I: Liver of animals treated with MNU plus sDHA (103.9 mg/kg), showing positive immunoreactive nuclear expression for Bcl-2 (less than 25 % positivity).

MNU: N-methyl-N-nitrosourea, DHA: Dihydroartemisinin, sDHA: Disulphide-substituted dihydroartemisinin

Key: Central vein (CV), Hepatocyte (H), Bcl-2 (→), Bile duct (BD), Hepatic Artery (HA), and Hepatic vein (HV).












Fig. 6. Photomicrographs showing hepatic cell expression of Ki67 in MNU treated and MNU plus DHA, sDHA or cyclophosphamide treated Sprague-Dawley rats (Ki67 immunohistochemical method, x400)

A: Liver of animals treated with distilled water (Control), showing negative immunostained cytoplasmic expression for Ki67 (less than 5 % positivity).

B: Liver of animals treated with MNU (50 mg/kg) alone, showing strong positive immunostained cytoplasmic expression for Ki67 (more than 75 % positivity).

C: Liver of animals treated with MNU plus cyclophosphamide (0.7 mg/kg), showing negative immunostained cytoplasmic expression for Ki67 (less than 5 % positivity).

D: Liver of animals treated with MNU plus DHA (54.8 mg/kg), showing positive immunostained cytoplasmic expression for Ki67 (less than 25 % positivity).

E: Liver of animals treated with MNU plus DHA (109.5 mg/kg), showing positive immunostained cytoplasmic expression for Ki67 (<25 % positive cells).

F: Liver of animals treated with MNU plus DHA (164.3 mg/kg), showing negative immunostained cytoplasmic expression for Ki67 (<10 % positive cells).

G: Liver of animals treated with MNU plus sDHA (34.6 mg/kg), showing very strong positive immunostained cytoplasmic expression for Ki67 (<60 % positive cells).

H: Liver of animals treated with MNU plus sDHA (69.3 mg/kg), showing positive immunostained cytoplasmic expression for Ki67 (<50 % positivity).

I: Liver of animals treated with MNU plus sDHA (103.9 mg/kg), showing positive immunostained cytoplasmic expression for Ki67 (< 50 % positivity).

MNU: N-methyl-N-nitrosourea, DHA: Dihydroartemisinin, sDHA: Disulphide-substituted dihydroartemisinin

Key: Hepatocyte (H), Hepatic vein (HV), Hepatic Artery (HA), Bile duct (BD), Ki67 (→), Central vein (CV) and Sinusoidal lining (SL)